Biologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA
|
|
- Elaine Alexander
- 6 years ago
- Views:
Transcription
1 Biologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA Overview Indications and Drug Selection Contraindications and safety Immunomodulators Optimization Controversies Page 1 of 26
2 Anti-TNF Agents for CD or UC Infliximab Adalimumab Golimumab Certolizumab Pegol VL VH PEG No Fc CH 1 Mouse Human PEG, polyethylene glycol. IgG 1 Chimeric monoclonal antibody (75% human IgG 1 isotype) IgG 1 Human recombinant antibody (100% human IgG 1 isotype) PEG Humanized Fab fragment (95% human IgG 1 isotype) Selective Adhesion Molecules in IBD Natalizumab: Humanized mab to α4β1 Nonselective: Associated with PML Vedolizumab: (MLN-002) Humanized mab to α4β7 - Selective to GI tract Page 2 of 26
3 Overview Indications and drug selection Contraindications and safety Immunomodulators Optimization Controversies Background Anti-TNF antibodies and Anti-Integrin therapies are the most effective approved therapies available to treat IBD Select patients who will benefit: those with active inflammatory disease, ideally before onset of complicated disease behavior Prior to and after initiation of biologic therapy it is important to be aware of safety risks, and attempt to avoid adverse events that are preventable Optimal and more durable response is obtained when combined with an immune modulator Need to select the correct population Lymphoma : Especially < 30 yo and > 50 yo: Male >> Female Therapeutic Drug Monitoring is advantageous Page 3 of 26
4 I. Indications and Drug Selection: Consider the Clinical Scenario Disease: Crohn s disease or ulcerative colitis Age of patient Severity of flare Hospitalized or outpatient? Refractory to conventional therapy which medication(s) were used previously? Fistulizing Crohn s disease Extraintestinal manifestations Post-operative prophylaxis in Crohn s disease? Newly diagnosed? Patient Prognosis Anti TNF: Drug Selection by Indication Infliximab Adalimumab Certolizumab Pegol Golimumab Luminal CD Fistulizing CD Mild to Moderate UC (Outpatient) Moderate to Severe UC (Hospitalized) Pregnancy Extraintestinal manifestations Page 4 of 26
5 Anti-Integrin: Drug Selection by Indication Natalizumab Vedolizumab Luminal CD Fistulizing CD Mild to Moderate UC (Outpatient) Moderate to Severe UC (Hospitalized) Pregnancy Critical Component Presence of Inflammation The key patient selection factor for treatment with Anti-TNF therapy and Anti-Integrin therapy Page 5 of 26
6 SONIC Corticosteroid-Free Clinical Remission at Week 26 in Patients With Crohn s Disease by Baseline Endoscopy Status AZA + placebo (n=170) IFX + placebo (n=169) IFX + AZA (n=169) Proportion of Patients (%) P=0.002 P=0.12 P=0.37 P=0.69 P=0.14 P= /115 P< /99 68/111 Lesions (n=325) P= P= /27 12/36 12/30 6/28 13/34 16/28 No Lesions (n=93) No Endoscopy or UTD (n=90) AZA, azathioprine; IFX, infliximab; UTD, unable to determine Colombel JF et al. N Engl J Med. 2010;362:1383. Biologic Therapy: Contraindications and Safety Infection TB HBV HIV Serious Infections: Abscess, Sepsis, Congestive heart failure Multiple sclerosis/demyelinating disease Lymphoproliferative disorder Other Malignancies? Inability to give informed consent or does not desire biologic Page 6 of 26
7 Anti-TNF Therapy: Risk for Serious Opportunistic Infections Pneumocystosis Histoplasmosis Candidiasis Listeriosis CMV Atypical mycobacteria Aspergillosis Cocidiomycosis Cryptococcus Herpetic Salmonellosis Legionellosis Blastomycosis Other Source: 1.) 2.) 3.) 4.) Minimizing Toxicity for Anti-TNF and Anti-Integrin Therapy Exclude TB prior to initiation (Anti-TNF) CXR, ppd, quantiferon TB gold If immunocompromised, PPD and TB may be negative Exclude the presence of active infection prior to initiation Abscess, C. difficile, CMV Check serology for Hepatitis B Vaccination for age-appropriate disease Influenza, hepatitis A and B, pneumococcal pneumonia, herpes zoster Kane S. Curr Gastroenterol Rep. 2010;12(6): Page 7 of 26
8 Vaccines in IBD Patients Source: General Vaccination Considerations In the IBD Patient Titers to check at first office visit: MMR If vaccination history unknown Varicella If vaccination history or history of chicken pox/zoster unknown Hepatitis A Except those with evidence of protective titer within 5 years of vaccine administration Hepatitis B Except those with evidence of protective titer within 5 years of vaccine administration Vaccinations to administer in specific patient groups regardless of immunosuppressive drug use: Tdap Hepatitis A HPV Hepatitis B Influenza Meningococcal Pneumococcal Vaccinations to consider if NO plans to start immunosuppressive therapy in 4-12 weeks: MMR Varicella Zoster Wasan SK, et al. Am J Gastroenterol. 2010;105(6): DiPalma J, et al. Gastroenterol Hepatol (N Y). 2011;7: Page 8 of 26
9 Consider Avoidance of AntiTNF Mechanism Prior TB (also Histoplasmosis, Aspergillosis, etc.) Prior Melanoma CHF (NYHA class III, IV) Prior Multiple Sclerosis / Optic Neuritis Prior AntiTNF mediated Pustular Psoriasis Prior Anti-TNF Drug Induced SLE reaction? Prior other malignancies? Prior Anti-TNF primary failure - if TDM done Consider Use of AntiTNF Mechanism over Anti-Integrin Mechanism Severe Fistulizing Crohn s Sever Hospitalized UC /CD need acute onset of action Pregnancy more data that anti-integrin (VEDO is class B) Prior VEDO failure (? With dose escalation to 300 mg iv every 4-6 weeks: since no TDM available) (Note: Dose escalation of VEDO is not an approved dosage) Page 9 of 26
10 Overview Indications and drug selection Contraindications and safety Immunomodulators Optimization Current Medical Therapy Inadequacy Our Current Medical therapy for IBD is effective in some patients. There is a large unmet need for IBD patients with our current medical therapy We are learning how to better use the medications we have and optimize therapy Combination Therapy Gary R. Lichtenstein, MD Therapeutic Professor Drug of Medicine Monitoring Prognostication Director, Center for IBD University of Pennsylvania School of Medicine There still remain Philadelphia, a large PA number of patients that face surgery with IBD; though there has been improvement Continued and future research focusing of disease treatment is needed. Page 10 of 26
11 ACCENT I, CHARM and PRECISE 2 40% 30% 20% 10% 0% 40% 30% 20% 10% 0% Clinical Remission in UC: ACT (Infliximab), ULTRA-2 (Adalimumab) and PURSUIT (Golimumab) Infliximab 8 Weeks ** ** Infliximab 10 mg/kg Infliximab 5 mg/kg Placebo Infliximab 54 Weeks ** ** Infliximab 10 mg/kg Infliximab 5 mg/kg 1 Placebo Patients failing 5-ASA/Steroids/IS 40% 30% 20% 10% 40% 30% 20% 10% 0% 0% Adalimumab 8 Weeks Adalimumab Placebo Adalimumab 52 Weeks Adalimumab Placebo 1.) Rutgeerts P, et al. N Engl J Med. 2005;353: ; 2.) Sandborn WJ, et al. Gastroenterology. 2012;142: ; 3.) Sandborn WJ, et al. Gastroenterology. 2014;146:85-95; 4.) Sandborn WJ, et al. Gastroenterology. 2014;146:96-109; 1 ** * % 30% 20% 10% 0% 40% 30% 20% 10% 0% Golimumab 6 Weeks ** ** Golimumab 400/200 mg Golimumab 100 mg Golimumab 200/100 mg Golimumab 50 mg Placebo Golimumab 54 Weeks ** Placebo * P<.05 versus placebo; ** P<.01 versus placebo 4 Page 11 of 26
12 Approaches Targeting Leukocyte Trafficking A B αlβ2 αmβ2 α4β7 α4β1 αlβ2 αmβ2 α4β7 α4β1 ICAM-2 ICAM-1 MAdCAM-1 VCAM-1 ICAM-2 ICAM-1 MAdCAM-1 VCAM-1 Natalizumab, AJM300 Vedolizumab, AMG 181, Etrolizumab, PF-00547,659 Danese S, et al. Gastroenterology. 2014;147(5): Page 12 of 26
13 Vedolizumab in Crohn s Disease: Clinical Remission at Week 6 and 10 Patients, % P=.05 Clinical Remission at Week Overall population 31.4 Failure Naïve TNF antagonist experience Placebo Patients, % P=.001 Clinical Remission at Week 10 P< Overall population Vedolizumab Q8W 35.3 Failure Naïve TNF antagonist experience Sands BE et al. Gastroenterology. 2014;147: GEMINI I Week 6 Results: Clinical Response and Remission in TNF Failure and TNF-Naïve Patients (Exploratory Endpoints) TNF Failure TNF-Naive (13.7, 39.9)* (3.9, 32.9)* (2.4, 30.2)* (-9.8, 22.8)* *95% CI for difference from placebo. Clinical response was defined as reduction in complete Mayo score of 3 points and 30% from baseline with an accompanying decrease in rectal bleeding subscore of 1 point or absolute rectal bleeding subscore of 1 point. Clinical remission was defined as a complete Mayo score of 2 points and no individual subscore >1 point. Feagan BG, et al. N Engl J Med. 2013;369: Page 13 of 26
14 GEMINI I Week 6 Results: Primary and Secondary Endpoints 100 Placebo, n=149 VDZ, n= P< P= Patients (%) P= Clinical response (Primary endpoint) Clinical remission (Secondary endpoint) Mucosal healing (Secondary endpoint) P values are vs placebo. Feagan BG, et al. N Engl J Med. 2013;369: GEMINI I Week 6 Results: Clinical Response and Remission in TNF Failure and TNF Naïve Patients (Exploratory Endpoints) TNF Failure Placebo, n=63 VDZ, n= TNF Naive Placebo, n=76 VDZ, n=130 (13.7, 39.9)* Patients (%) (3.9, 32.9)* Clinical response (-9.8, 22.8)* Clinical remission Patients (%) Clinical response (2.4, 30.2)* Clinical remission *95% CI for difference from placebo. Feagan BG, et al. N Engl J Med. 2013;369: Page 14 of 26
15 GEMINI I Week 52 Results: Primary and Key Secondary Endpoints 100 Placebo, n=126 VDZ Q8, n=122 VDZ Q4, n=125 Patients (%) P< P< P< P< Clinical remission (Primary endpoint) Mucosal healing (Secondary endpoint) P values are vs placebo. All patients were Week 6 responders Feagan BG, et al. N Engl J Med. 2013;369: Infusion-Related Reactions Infusion-related reactions (IRRs) and hypersensitivity reactions have occurred, including a case of anaphylaxis (1 out of 1434 patients treated with vedolizumab [0.07%]) Allergic reactions including dyspnea, bronochospasm, urticaria, flushing, rash, and increased blood pressure and heart rate have also been observed 4% of patients treated with vedolizumab experienced an IRR in GEMINI I and in GEMINI II, versus 3% of patients treated with placebo The most frequently observed IRRs in the patients treated with vedolizumab (reported more than twice) were nausea, headache, pruritus, dizziness, fatigue, infusion-related reaction, pyrexia, urticaria, and vomiting. Each of these adverse reactions occurred in <1% of all patients treated with vedolizumab and no individual adverse reaction reported occurred at a rate above 1% Less than 1% of patients treated with vedolizumab had IRRs assessed by the investigator as severe, and IRRs requiring discontinuation of study treatment occurred in <1% Vedolizumab [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc; May Page 15 of 26
16 Immunogenicity In GEMINI I and GEMINI II, in patients who received vedolizumab, the frequency of antibodies detected in patients was 13% at 24 weeks after the last dose of study drug (greater than 5 half-lives after last dose) During treatment, 56 of 1434 (4%) of patients treated with vedolizumab had detectable anti-vdz antibody at any time during the 52 weeks of continuous treatment Nine of 56 patients were persistently positive (at 2 or more study visits) for anti-vdz antibody and 33 of 56 patients developed neutralizing antibodies to vedolizumab Among 8 of these 9 subjects with persistently positive anti-vdz antibody and available vedolizumab concentration data, 6 had undetectable and 2 had reduced vedolizumab concentrations. None of the 9 subjects with persistently positive anti-vdz antibody achieved clinical remission at Weeks 6 or 52 in the controlled trials Vedolizimab [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc; May IBD: Issues With AZA / 6-MP Take 6-12 weeks to work Side effects Pancreatitis (4%), allergy (2%) Bone marrow suppression (4%) Liver toxicity (9%) Infection (serious infection: 2%) Increased risk of lymphoma Non-melanoma skin cancer Abnormal Pap smears Require frequent labs Complete blood count (CBC), liver function tests (LFTs) Candy S, et al. Gut. 1995;37(5): Pearson DC, et al. Ann Intern Med. 1995;123(2): Kotlyar D, et al, Clinical Gastroenterology and Hepatology 2015;13: Page 16 of 26
17 Maintenance of Remission with Azathioprine in Crohn s Disease Patients (%) P = NS 73 Azathioprine (n = 33) Placebo (n = 33) P = Week 12 CDAI < 150 Month 15 CDAI < 175 Candy S et al. Gut. 1995;37: Early AZA Alone Is Ineffective in CD Rate of Trimesters in Remission per Patient During First 3 y, % P = NS Sustained Steroid-Free Clinical Remission to Wk 76, % of Patients P = NS (n = 65) (n = 67) (n = 68) (n = 63) Abbreviation: Tx, transplantation. Left-side graph: Cosnes J, et al. Gastroenterology. 2013;145(4): Right-side graph: Panés J, et al. Gastroenterology. 2013;145(4): Page 17 of 26
18 Risk of Lymphoma with AZA / 6-MP Use 18 studies (among 4383 citations) met inclusion criteria. The SIR for lymphoma was Overall (95% CI, ), 2.80 (95% CI, ) in 8 population studies 9.24 (95% CI, ) in 10 referral studies. Population studies demonstrated an Increased risk among current users (SIR=5.71; 95% CI, ) but No increased risk in former users (SIR=1.42; 95% CI, ). Kotlyar D, et al, Clinical Gastroenterology and Hepatology 2015;13: Risk of Lymphoma with AZA / 6-MP Use Risk Became Significant after One year of exposure Sex* Men have a greater risk than women (RR = 1.98; P <.05) Both sexes were at increased risk for lymphoma Men: SIR for men = 4.50 ( 95% CI ) Women: SIR for women = 2.29 (95% CI ) Age Age 30-59: 1 lymphoma per 2000 pt-yrs of followup Patients < 30 years had the highest RR o SIR=6.99 (CI, 95% CI, ) o Younger men had the highest risk: Men < 30 : SIR~ 9 The absolute risk was highest in patients > 50 years 1:354 cases per patient year RR=4.78 *- subanalysis of 2 studies Kotlyar D, et al, Clinical Gastroenterology and Hepatology 2015;13: Page 18 of 26
19 Steroid Sparing and Toxicity of MTX in Active CD % P =.025 Placebo (n = 47) MTX 25 mg/wk IM (n = 94) % Patients % 17% P = % Able to Discontinue Steroids Unable to Tolerate Medication Feagan BG et al. N Engl J Med. 1995;332:292. Maintenance of Remission with Methotrexate in Crohn s Disease 100 Patients in remission (%) P =.04 Methotrexate Placebo Week Feagan BG et al. N Engl J Med. 2000;342: Page 19 of 26
20 Issues With MTX Often used intramuscularly in Crohn s Disease 1 Common side effects: 1 Nausea/vomiting Bone marrow suppression Scarring of the liver Liver biopsy is needed before and during MTX therapy in certain patients 1 Requires continuous monitoring of CBC and LFTs 2 Contraindicated if attempting pregnancy 2 Category X 1. Lichtenstein GR, et al. Am J Gastroenterol. 2009;104(2): Methotrexate injection USP [package insert]. Lake Forest, IL: Hospira, Inc.; Overview Indications and drug selection Contraindications and safety Immunomodulators Optimization Page 20 of 26
21 Defining anti-tnf failure: Secondary Non-response (Loss of Response) Pseudo-failure for symptoms unrelated to active inflammation Pharmacokinetic Inadequate drug levels because of anti-drug antibody Inadequate drug levels because of rapid drug clearance for other reasons Inadequate dose Pharmacodynamic Evolution of resistance to anti-tnf mechanism Dose-limiting adverse event Optimal Therapy with Anti-TNFs: Maximizing Efficacy and Avoiding Loss of Response Give a loading dose Infliximab 5 mg/kg IV at weeks 0, 2 and 6 Adalimumab 160 mg, 80 mg, 40 mg SC EOW Certolizumab pegol 400 mg SC EOW x3 Golimumab 200 mg sq at 0 then 100 mg at 2 wks Give in combination with an immune modulator (mercaptopurine, azathioprine, or methotrexate) If not given in combination with immune modulator, consider infliximab with hydrocortisone pretreatment Avoid episodic dosing Consider smoking cessation Dose optimize early to avoid unintentional episodic dosing? Page 21 of 26
22 Why Give Concomitant Therapy? Lower rates of infusion reactions (best defined with infliximab) Lower rates of anti-drug antibody formation Higher drug levels (independent of effect on antibody formation) Independent effect of a 2 nd active agent Lower rate of loss of response No signal for increased risk of infection (SONIC) Concomitant Treatment with AZA and IFX is Associated with Higher Serum IFX Levels in SONIC Median serum infliximab trough concentrations at Week 46 Median serum infliximab trough concentration* at Week 46 (µg/ml) IFX (n=73) p< IFX/AZA (n=76) *infliximab- or infliximab/azathioprine-treated patients who had serum samples collected prior to infusion at Week 46 (N=149) Colombel JF, et al. New Engl J Med 2010;362: Page 22 of 26
23 UC SUCCESS: Combination Therapy in UC Primary Endpoint: Steroid-Free Remission at Week 16 P=0.017 Percent of Patients (%) P=0.813 P=0.032 n=18 n=17 n=31 Panaccione R, et al. Gastroenterology 2014; 146(2): Assessing Loss of Response Confirmed Active Inflammation Subtherapeutic concentration and positive ADA Therapeutic drug concentration or detectable trough level Subtherapeutic concentration or undetectable trough level Change to another anti-tnf agent If persistent disease Change to treatment with different MOA (non-anti-tnf agent) or Increase dose frequency Consider adding immunosuppressant (if monotherapy) ADA, anti-drug antibodies. Afif W et al. Am J Gastroenterol. 2010;105: Page 23 of 26
24 Treating IBD Beyond Symptoms: Rationale for a Clear Management Strategy Personalized management for IBD will depend on Disease severity at presentation Clinical and biologic prognostic factors Achievement of clinical and biologic remission Maintenance of clinical and biologic remission Patient adherence Therapeutic monitoring Pharmacoeconomics 47 AGA Clinical Pathway for Crohn s Disease: Characterizing Risk Low Risk High Risk >30 years Age at diagnosis <30 years Limited Anatomic involvement Extensive No Perianal and/or severe rectal disease Superficial Ulcers Deep No Prior surgical resection Yes Yes No Stricturing and/or penetrating behavior Yes Sandborn WJ. Gastroenterology. 2014;147: Page 24 of 26
25 AGA Clinical Pathway for Crohn s Disease: Initial Treatment Low-risk patient Ileum and/or proximal colon, none to minimal symptoms Options Budesonide 9 mg/day with or without AZA Tapering course of prednisone with or without AZA Diffuse or left colon, none to minimal symptoms Options Tapering course of prednisone with or without AZA Moderate/high-risk patient Options Anti-TNF monotherapy over no therapy or thiopurine monotherapy Anti-TNF + thiopurine over thiopurine monotherapy or anti-tnf monotherapy Methotrexate for patients who do not tolerate purine analog in combination with anti-tnf Sandborn WJ. Gastroenterology. 2014;147: Is A Treat-to-Target Approach Feasible in IBD? Symptoms QoL Labs CRP Calprotectin? Mucosal healing Hospitalizations Surgery Biologic (Deep remission) Histologic remission Disease modification 50 Page 25 of 26
26 Conclusions Document active inflammation before initiating anti-tnf or anti-integrin Therapy Always consider combination therapy Avoid episodic dosing Treat active infection before starting anti-tnf or anti-integrin Therapy Prevent preventable infections with vaccination Optimize therapy Prognosticate to use appropriate therapy Use biologic (Anti-TNF / Anti-Integrin) therapy in appropriate patient populations and avoid use in specific populations when inappropriate. Page 26 of 26
Biologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationSevere IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationPositioning New Therapies
Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed
More informationEmerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD
Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Gary R. Lichtenstein, MD, FACG Professor of Medicine Director, Inflammatory Bowel Disease Program University of Pennsylvania Philadelphia, PA In my
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationPractical Risk Management Tools for Patients with IBD. Garth Swanson MD Rush University Medical Center
Practical Risk Management Tools for Patients with IBD Garth Swanson MD Rush University Medical Center IBD Therapy Severity Tysabri Surgery Infliximab, i Adalimumab, Certilizumab Corticosteroids, Immunomodulators
More informationBiologic Therapy for Ulcerative Colitis in 2015
5/6/215 Biologic Therapy for Ulcerative Colitis in 215 John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University Bressler B, Marshall JK, et al. Gastroenterology 215;148: 135-58
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationJoin the conversation at #GIFORUMCCFA
1 Join the conversation at #GIFORUMCCFA 2 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the
More informationSelby Inflamm Bowel Dis. 2008:14:
Medical Management of Inflammatory Bowel Disease Freddy Caldera D.O. Assistant Professor Division of Gastroenterology Objectives Discuss Crohn s disease and Ulcerative Colitis Discuss Medications for Inflammatory
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationNew treatment options in IBD: today and the future. Silvio Danese Istituto Clinico Humanitas, Milan, Italy
New treatment options in IBD: today and the future Silvio Danese Istituto Clinico Humanitas, Milan, Italy Date of preparation: October 2014 GLO/EYV/2014-00010h Overview of the late-stage IBD drug pipeline*
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationSelection and use of the non-anti- TNF biological therapies: Who? When? How?
Selection and use of the non-anti- TNF biological therapies: Who? When? How? Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz Division of Gastroenterology The Icahn School of Medicine
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationLatest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D.
Latest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D. Co-Director, IBD Center Director, Nutrition Support Service UPMC Presbyterian Hospital Division of Gastroenterology,
More informationBiologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationAssociation Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean Frédéric Colombel, William J. Sandborn, Matthieu Allez, Jean Louis Dupas, Olivier
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationCROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM
CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM Crohn's Disease Ulcerative Colitis Steroids x 2 No prior AZA/6-MP Biologic Agent AZA/6-MP STEP-UP MANAGEMENT APPROACH Advantages Patients attain remission
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationPreventive Care and Monitoring of the IBD Patient
Preventive Care and Monitoring of the IBD Patient Francis A. Farraye, MD, MSc, FACG Clinical Director, Section of Gastroenterology Director, Inflammatory Bowel Disease Center Boston Medical Center Professor
More informationCOPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease
Inflammatory Bowel Disease What Every Clinician Needs to Know Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard
More informationThe Refractory Crohn s Disease
The Refractory Crohn s Disease Patient David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationProgress in Inflammatory Bowel Disease
Progress in Inflammatory Bowel Disease Gary R Lichtenstein, MD Director, Center for IBD University of Pennsylvania School of Medicine Hospital of the University of PA Philadelphia, PA Disclosure Research,
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Brian Feagan, MD, FACG Professor of Medicine and Epidemiology and Biostatistics Director, Robarts Clinical Trials Robarts Research Institute University
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Sunanda Kane, MD, FACG Professor of Medicine Department of Gastroenterology and Hepatology Mayo Clinic Rochester, MN In my lecture today, I will be
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationNew and Future Adhesion Molecule Based Therapies in IBD
New and Future Adhesion Molecule Based Therapies in IBD Brian G. Feagan Professor of Medicine, Epidemiology and Biostatistics University of Western Ontario Robarts Clinical Trials London, Ontario, Canada
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationEmerging Therapies in IBD 2006
Overview Emerging Therapies in IBD 26 David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Describe the unmet needs of therapy in IBD Emerging biologic
More informationIBD Biologicals and Novel therapeutic regimes. Dr S K Sinha Additional Professor Department of Gastroenterology PGIMER, Chandigarh
IBD Biologicals and Novel therapeutic regimes Dr S K Sinha Additional Professor Department of Gastroenterology PGIMER, Chandigarh 1 Treatment aims in IBD Traditional treatment goals of IBD Control of symptoms?improvement
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Francis A. Farraye, MD, MSc, FACG Professor of Medicine Clinical Director, Section of Gastroenterology Boston University School of Medicine Boston,
More informationImmunogenicity of Biologic Agents and How to Prevent Sensitization
Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning
More informationGionata Fiorino VEDOLIZUMAB E IBD. Un nuovo target terapeutico
Gionata Fiorino VEDOLIZUMAB E IBD Un nuovo target terapeutico Anti cell adhesion molecules Danese S, NEJM 2011 6 Steps leukocyte recruitment Fiorino G. et al. 2010 Vedolizumab Blocks Fewer Biological Pathways
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationPerianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification
More informationOUNCE OF PREVENTION WORTH A POUND OF CURE
Healthcare maintenance in the patient with Inflammatory Bowel Disease. OUNCE OF PREVENTION WORTH A POUND OF CURE Your gastroenterologist is NOT your primary care physician Your gastroenterologist is NOT
More informationAre Biologicals Safe Enough?
Are Biologicals Safe Enough? Dr Anne Duggan Director of Gastroenterology, John Hunter Hospital, Hunter New England Area Health Service (HNEAHS) Conjoint A/Professor, University of Newcastle, Australia
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationBalancing the Risk and Benefit of Immunomodulator and Biologic Therapy in Patients with IBD
Balancing the Risk and Benefit of Immunomodulator and Biologic Therapy in Patients with IBD Gary R. Lichtenstein, MD Professor of Medicine University of Pennsylvania School of Medicine Director, Center
More informationUlcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13
Ulcerative Colitis Therapy Amy Morse November 30/13 GI for GP s Jasper AB Faculty Disclosure Faculty: Amy Morse Relationships with commercial interests: Grants/Research Support: Therapeutic Fellowship
More informationLatest Meds Approved for IBD: What are they and how do they work?
Latest Meds Approved for IBD: What are they and how do they work? JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER SEPT 30, 2018 Brief history of IBD Dr. Burrill Crohn JAMA
More informationUNC INFLAMMATORY BOWEL DISEASE DRUG PROTOCOL VEDOLIZUMAB (ENTYVIO)
UNC INFLAMMATORY BOWEL DISEASE DRUG PROTOCOL VEDOLIZUMAB (ENTYVIO) TREATMENT PROTOCOL: Vedolizumab is a humanized immunoglobulin G1 monoclonal antibody that targets 41 integrin and blocks its interaction
More informationOptimizing Therapies for Severe Ulcerative Colitis October 19, 2014
Optimizing Therapies for Severe Ulcerative Colitis October 19, 2014 Ellen J. Scherl, MD, FACP, FACG, AGAF, FASGE, NYSGEF Director Jill Roberts Center for Inflammatory Bowel Disease Jill Roberts IBD Research
More informationCarefirst.+.V Family of health care plans
Carefirst.+.V Family of health care plans CVS care mark POLICY Document for ENTYVIO The overall objective of this policy is to support the appropriate and cost effective use of the medication, specific
More informationHow to use infliximab?
How to use infliximab? Séverine Vermeire, MD, PhD Division of Gastroenterology University Hospital Gasthuisberg Leuven The how to use infliximab rules Before starting IFX: try optimizing chances for response!
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationΑπό τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων
Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων Conflict of interest By means of this, the speaker confirms that
More informationVedolizumab: policing leukocyte traffic
Oxford Inflammatory Bowel Disease MasterClass Vedolizumab: policing leukocyte traffic Dr Brian Feagan, London, Canada Vedolizumab : Policing Lymphocyte Traficking Brian G. Feagan Professor of Medicine,
More informationHow do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
More informationOptimal Use of Immunomodulators and Biologics
3/17/214 Optimal Use of Immunomodulators and Biologics Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota, U.S.A. Loftus Disclosures
More informationTreatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG
Treatment of Inflammatory Bowel Disease Michael Weiss MD, FACG What is IBD? IBD is an immune-mediated chronic intestinal disorder, characterized by chronic or relapsing inflammation within the GI tract.
More informationTherapy for Inflammatory Bowel Disease
Therapy for Inflammatory Bowel Disease Jonathan P. Terdiman, MD Professor of Clinical Medicine Clinical Director, Center for Colitis and Crohn s Disease University of California San Francisco, CA UC: Current
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More informationWHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY?
WHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY? Siew Ng, Professor MBBS, FRCP, (Lon, Edin), PhD (Lond), AGAF, FHKCP, FHKAM (medicine) Department of Medicine and Therapeutics Chinese University
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationObjectives. Overview 11/4/2014. Modern Management of Inflammatory Bowel Disease Daniel J. Stein MD Assistant Professor Medical College of Wisconsin
Modern Management of Inflammatory Bowel Disease Daniel J. Stein MD Assistant Professor Medical College of Wisconsin Objectives Review of Crohn s Disease and UC Approach to Therapy Summarize the benefits
More informationClinical Policy: Vedolizumab (Entyvio) Reference Number: CP.PHAR.265
Clinical Policy: (Entyvio) Reference Number: CP.PHAR.265 Effective Date: 07/16 Last Review Date: 07/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationManagement of Moderate to Severe Ulcerative Colitis
Management of Moderate to Severe Ulcerative Colitis Neilanjan Nandi, MD Assistant Professor of Medicine Associate Program Director Division of Gastroenterology Drexel University College of Medicine Hahnemann
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Community Plan Medical Benefit Drug Policy Policy Number: CS2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationAgenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease
Agenda Predictive markers in IBD Management of ulcerative colitis Management of Crohn s disease 2 Patients With UC (%) Distribution of UC Disease Severity at Presentation 1 Fulminant disease (9%) 8 6 4
More informationPredicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab.
Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab. Dr Peter Irving Guy s and St Thomas Hospital, London King s College London Response to vedolizumab
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: Feb. 14, 2018 Last Revised: April 1, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationAdverse Events From Biologic Agents in IBD
Adverse Events From Biologic Agents in IBD David A. Schwartz, MD, FACG Director, Inflammatory Bowel Disease Center Professor of Medicine Vanderbilt University Medical Center Case Page 1 of 24 28 yo with
More informationBiologics, Novel Therapeutic Approaches in Inflammatory Bowel Diseases
Biologics, Novel Therapeutic Approaches in Inflammatory Bowel Diseases Walter Reinisch Univ-Klinik für Innere Medizin III Abt. Gastroenterologie & Hepatologie AKH Wien The Biologic s evolution From availabilitydriven
More informationPediatric Inflammatory Bowel Diseases
Pediatric Inflammatory Bowel Diseases Michael Stephens, M.D. Denny Sanford Pediatric Symposium November 21 2014, Sioux Falls, SD 2014 slide-1 Disclosures I have nothing to disclose 2014 slide-2 Objectives
More informationDRAFT. Remission rates, calculated using observed case (OC) analyses were as follows: Year 1 Year 2 Year 3 Year 4 All patients 62.
DRAFT New Efficacy Data Shows Cimzia (certolizumab pegol) Provides Long-Term Remission of Moderate to Severe Crohn s Disease Regardless of Prior Anti-TNF Exposure, According to Data Presented at DDW Oral
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationModern Management of Perianal Fistulas in Crohn s Disease (PFCD): Future Directions
Modern Management of Perianal Fistulas in Crohn s Disease (PFCD): Future Directions Rami Ismail, Pharm.D., BCPS, BCCCP, CACP Lead Clinical staff Pharmacist, Cleveland Clinic Abu Dhabi Disclosure Information
More informationPersonalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment
Personalized Medicine Selecting the Right First-line Biologic Agent William Tremaine, M.D. Maxine and Jack Zarrow Professor Mayo Clinic Rochester, MN, USA The Right Treatment Pretreatment Genomic Analysis
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ENTYVIO safely and effectively. See full prescribing information for ENTYVIO. ENTYVIO (vedolizumab)
More informationTherapies for IBD: the Pipeline. New Therapeutic Agents in IBD
Therapies for IBD: the Pipeline New Therapeutic Agents in IBD William J. Sandborn, MD Professor & Chief, Division of Gastroenterology Director, UCSD IBD Center Budesonide Oral MMX budesonide Rectal budesonide
More informationOPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG
1C: Advances in Inflammatory Bowel Disease OPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG narrow interpretation of this presentation topic would A be a discussion of dosing
More informationDENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease
Measure #270: Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationPEDIATRIC INFLAMMATORY BOWEL DISEASE
PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric Gastroenterology Advocate Children s Hospital Disclosers Abbott Nutrition - Speaker Inflammatory Bowel Disease Chronic inflammatory disease
More informationOptimizing the treatment of IBD through use of therapeutic drug monitoring
Optimizing the treatment of IBD through use of therapeutic drug monitoring Adam S. Cheifetz Director, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center Associate Professor of
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ENTYVIO safely and effectively. See full prescribing information for ENTYVIO. ENTYVIO (vedolizumab)
More informationRisk = probability x consequence
Explaining Risks of IBD Therapy to Parents and Patients December 4, 2009 CCFA Advances in IBD Hollywood, FL Corey A. Siegel Assistant Professor of Medicine, Dartmouth Medical School Director, Dartmouth-Hitchcock
More informationNEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL
NEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL CROHN S DISEASE Chronic disease of uncertain etiology Etiology- genetic, environmental, and infectious Transmural
More information